glp-1 receptor brain biology: structure, signaling, and distribution GLP-1 drugs protect brain health

Coverage for diabetes treatment has been relatively stable, with nearly 60% of employers now offering it

Levothyroxine: therapeutic use and regulatory issues related to bioequivalence

While these medications offer new hope for adolescents struggling with obesity, their use must be guided by evidence-based protocols, careful patient selection, and ongoing research to address remaining knowledge gaps

GLP-1 receptor agonists have transformed weight loss treatment for millions of adults, but breastfeeding mothers face unique safety questions that require careful consideration

These mechanisms work by promoting vasodilation, reducing arterial stiffness, and improving lipid profiles, with many patients in clinical trials finding substantial reductions in heart attack and stroke risk, ultimately delivering enhanced cardiac outcomes alongside metabolic improvements

In December 2025, the administration also introduced the BALANCE (Better Approaches to Lifestyle and Nutrition for Comprehensive hEalth) model, a five year CMS Innovation Center (CMMI) model that intends to expand access to obesity drugs in Medicaid and Medicare by negotiating lower GLP-1 prices with manufacturers